BCBS Kansas Medical Policy Updates – September 2018

Click here to view the Blue Cross Blue Shield Kansas Medical Policy Updates »

September 2018 BCBS Kansas Medical Policy Updates:

• Corneal Collagen Cross-Linking
• Coronary Computed Tomography Angiography with Selective Noninvasive Fractional Flow Reserve
• Cryosurgical Ablation of Primary or Metastatic Liver Tumors
• Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) (replaces Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor))
• Diagnosis and Treatment of Sacroiliac Joint Pain
• Electronic Brachytherapy for Nonmelanoma Skin Cancer
• Endari™ (L-glutamine)
• Extracorporeal Shock Wave Therapy (ESWT) for Plantar Fasciitis and Other Musculoskeletal Conditions
• Genotype-Guided Tamoxifen Treatment
• Hemlibra® (emicizumab-kxwh)
• In Vitro Chemoresistance and Chemosensitivity Assays
• KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy
• KRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer
• Laboratory Tests for Heart Transplant Rejection
• Lumbar Spinal Fusion
• Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders
• Miscellaneous Genetic and Molecular Diagnostic Tests
• Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
• Molecular Markers in Fine Needle Aspirates of the Thyroid
• Opioid Immediate Relea
• Opioids, Extended Release (ER)
• Otezla (apremilast)
• PDF: BiologicImmunomodulatorsTherapy_2018-09-26.pdf
• PDF: SelfAdministeredOncologyAgents_2018-09-26.pdf
• Percutaneous Vertebroplasty and Sacroplasty
• Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors
• Risk-Reducing Mastectomy
• Scanning Computerized Ophthalmic Diagnostic Imaging Devices
• Self Administered Oncology Agents
• Spinraza™ (nusinersen)
• Substrate Reduction Therapy
• Synagis (palivizumab)
• Topical Doxepin
• Tumor Treating Fields Therapy
• Tysabri  (natalizumab), Lemtrada™ (alemtuzumab), and Ocrevus  (ocrelizumab) (IV Multiple Sclerosis Agents)
• Ultrasonographic Measurement of Carotid Intima-Medial Thickness as an Assessment of Subclinical Atherosclerosis
• Xermelo (telotristat)
• Xolair® (omalizumab)

Click here to view the Blue Cross Blue Shield Kansas Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.